Amit Bahl explains why 3-weekly cabazitaxel is still a valid option for treatment-naïve, HER2-negative, metastatic breast cancer even though the CONCEPT trial failed to show its superiority over weekly paclitaxel in this setting.

The radiolabeled small molecule lutetium-177-prostate-specific membrane antigen-617 offers higher activity and better patient-reported outcomes than cabazitaxel in metastatic castration-resistant prostate cancer, research shows.

Cabazitaxel could be an option for men with metastatic castration-resistant prostate cancer who have progressed after treatment with docetaxel and an androgen signaling-targeted agent, suggest trial findings.

Ronald de Wit tells us why the CARD trial results are likely to change the paradigm for the treatment of metastatic castration-resistant prostate cancer (3:58).

Cabazitaxel Accord received a recommendation for marketing authorization from the EMA’s Committee for Medicinal Products for Human Use.

The patient-reported outcomes from the CARD trial of third-line cabazitaxel in men with metastatic castration-resistant prostate cancer add support for using the taxane in this setting, say researchers.

Phase I/II research published in The Lancet Oncology shows that combining cabazitaxel with carboplatin has the potential to prolong progression-free survival in men with metastatic castration-resistant prostate cancer.

Overall survival rates among men receiving cabazitaxel for metastatic castration-resistant prostate cancer are lower in everyday oncology practice than previously observed in clinical trials, French study data show.

But the Committee was unable to conclude that cabazitaxel offers equivalent efficacy and safety to docetaxel and refused the application.

The recommended cabazitaxel regimen is now 20 mg/m 2 every 3 weeks given as a 1-hour intravenous infusion plus oral prednisone 10 mg/day, with the higher cabazitaxel dose allowed in select patients at the physician’s discretion.

The double-blind SAKK 08/16 trial enrolled 90 men who had nonprogressive disease after receiving docetaxel (86.7–95.6%) or cabazitaxel (4.4–13.3%), and had previously received abiraterone (60.0%), enzalutamide (31.1%), or both (8.9%).

Treatment with lutetium-177-prostate-specific membrane antigen-617 does not significantly prolong overall survival relative to cabazitaxel, suggest data from the TheraP study of patients with metastatic castration-resistant prostate cancer.

The dose-finding phase 1 part of the trial included 44 patients aged a median of 70 years with progressive disease who had received at least one prior AR axis inhibitor and at least one line of taxane-based chemotherapy; 55% had received both abiraterone and enzalutamide and 57% had received cabazitaxel.

The compounds in question were the mTOR/PI3K inhibitors everolimus, temsirolimus, and alpelisib, the antimetabolites gemcitabine and decitabine, the mitotic inhibitor cabazitaxel, and the kinase inhibitors crizotinib and dasatinib.

However, radiographic PFS was not significantly prolonged with olaparib versus cabazitaxel among participants who harbored variants in 12 other HRR genes (PROfound cohort B; nonsignificant HR=1.63), and the Bayesian analysis showed an 83% probability that cabazitaxel was superior in these patients.

All men were receiving ADT, either alone or alongside a chemotherapeutic agent (docetaxel or cabazitaxel), an androgen-targeting agent (abiraterone or enzalutamide), or radium-223.

Silke Gillessen comments on the phase IV CARD study investigating third-line cabazitaxel in men with metastatic castration-resistant prostate cancer (3:02). 

Michael Hofman explains why the TheraP study of LuPSMA versus cabazitaxel in men with metastatic castration-resistant prostate cancer is even more relevant in light of the recently reported CARD trial (4:24).

ASCO expert Robert Dreicer shares his views on the updates from the CARD, TITAN, and STOMP prostate cancer trials presented at ASCO GU 2020 (3:07). Read more about the STOMP trial and the CARD trial